Quarterly report pursuant to Section 13 or 15(d)

EQUITY

v3.7.0.1
EQUITY
6 Months Ended
Feb. 28, 2017
Equity [Abstract]  
EQUITY

NOTE 6 - EQUITY

 

Authorized Stock

 

On January 19, 2017, a majority of stockholders of our company and our board of directors approved a change of name of our company from Knight Knox Development Corp. to Reactive Medical Inc. and an increase to our authorized capital from 75,000,000 shares of common stock, par value $0.001 to 150,000,000 shares of common stock, par value $0.001 and 50,000,000 shares of preferred stock, par value $0.001.

 

Preferred shares

 

The Company has authorized 50,000,000 shares of preferred stock with a par value of $0.001.

 

During the six months ended February 28, 2017, there were no issuances of preferred stock.

 

Common Shares

 

The Company has authorized 150,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

 

During the six months ended February 28, 2017, there were no issuances of common stock.